0.22
0.00%
Close of 6 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About StimCell Enegetics
From its filings with the US Securities and Exchange Commission
StimCell Enegetics is based in Vancouver, British Columbia, Canada and is incorporated in Nevada. Its shares trade on OTC under the ticker STME. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 May 2024, it reported revenue of $0.
Stimcell Energetics Inc. was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed its wholly owned subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia.
Concurrent with the Reverse Split, the Company amended its articles of incorporation to change the Company’s name from “Cell MedX Corp.” to “Stimcell Energetics Inc.” (the “Name Change”).
Stimcell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications, including, but not limited to: aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company’s primary focus is on continued research and development of its eBalance® Technology and its eBalance® Home System.
The Company acquired its proprietary microcurrent technology designed to be used in the treatment of diabetes and related ailments (the “eBalance® Technology”) in 2014 through a Technology Purchase Agreement. eBalance® Technology is based on the science of bioelectric signals, their effect on epigenetic events within the human body, and ability to modify and affect the behavior of cells, tissues, and organs. The eBalance® Technology utilizes microcurrent electrical therapy (“MEY”) to deliver subsensory micro amperage current to the patient/user to support general wellness or provide temporary relief of pain.
Quoted from its 10-K, filed 31 Aug 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 11 Mar 2013
- Website
- cellmedx.com ↗
- Head office
- 820 - 1130 PENDER STREET, WEST, VANCOUVER, A1, V6E 4A4
- Incorporated in
- NV
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. David JeffsChief Executive Officer, Director, since 2023$90,000
- Ms. Yanika SilinaChief Financial Officer, Treasurer, Corporate Secretary, Director, since 2014$30,000
- Mr. Amir VahabzadehDirector
- Dr. George AdamsIndependent Director
- Mr. Joao Da CostaIndependent Director, since 2020$107,488
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cell MedX Corp. develops eBalance Technology for diabetes treatment and wellness products.
- Avyonce Cosmedics Inc. resells spa technology and equipment to the beauty industry.
- The company has a subsidiary focused on medical aesthetics education and observational studies.
Weaknesses
- Cell MedX Corp. has zero full-time employees and is a development stage company.
- The company went public in 2013 with no revenue yet.
- Avyonce Cosmedics Inc. is a subsidiary with limited commercial activity.
Opportunities
- eBalance Technology offers potential for diabetes treatment expansion in the Health Care sector.
- The beauty and wellness industry provides a growing market for spa technology reselling.
- Medical aesthetics education can attract more professionals in the Health Care industry.
Threats
- The development stage status may delay product commercialization.
- No revenue generation since IPO in 2013 poses financial risks.
- Avyonce's limited commercial activity could hinder growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.